Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

Clicks: 402
ID: 112689
1996
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clini …
Reference Key
dm1996antimicrobialphase Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lewinsohn DM;Bowden RA;Mattson D;Crawford SW;;
Journal Antimicrobial agents and chemotherapy
Year 1996
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8913463
Keywords
injections National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't u.s. gov't adult female male middle aged P.H.S. Clinical Trial antiviral agents / administration & dosage antiviral agents / therapeutic use* ribavirin / administration & dosage ribavirin / therapeutic use* respiratory syncytial virus infections / drug therapy* respiratory syncytial virus infections / virology pmid:8913463 pmc163574 doi:10.1128/aac.40.11.2555 phase i d m lewinsohn r a bowden s w crawford bone marrow transplantation / physiology* intravenous postoperative complications / drug therapy* postoperative complications / virology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.